As previously reported, Guggenheim analyst Debjit Chattopadhyay initiated coverage of Solid Biosciences (SLDB) with a Buy rating and $26 price target. Data to-date from its late-stage DMD gene therapy STG-003 appears to have addressed safety issues plaguing Sarepta’s (SRPT) Elevidys, says the firm, which anticipates a path towards accelerated approval for -003 as it views leadership changes at the CBER to be beneficial to Solid.
Claim 55% Off TipRanks
Trade SRPT with leveragePublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences initiated with a Buy at Guggenheim
- Solid Biosciences: De-Risking Duchenne Program and Advancing Gene Therapy Pipeline Supports Buy Rating and $19 Target
- Solid Biosciences files to sell 1.32M shares of common stock for holders
- Solid Biosciences files to sell 42.78M shares of common stock for holders
- Solid Biosciences reports Q4 EPS (53c), consensus (52c)